FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379744348> ?p ?o ?g. }

• W4379744348 endingPage "e1004245" @default.
• W4379744348 startingPage "e1004245" @default.
• W4379744348 abstract "An increased risk of myocarditis or pericarditis after priming with mRNA Coronavirus Disease 2019 (COVID-19) vaccines has been shown but information on the risk post-booster is limited. With the now high prevalence of prior Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, we assessed the effect of prior infection on the vaccine risk and the risk from COVID-19 reinfection.We conducted a self-controlled case series analysis of hospital admissions for myocarditis or pericarditis in England between 22 February 2021 and 6 February 2022 in the 50 million individuals eligible to receive the adenovirus-vectored vaccine (ChAdOx1-S) for priming or an mRNA vaccine (BNT162b2 or mRNA-1273) for priming or boosting. Myocarditis and pericarditis admissions were extracted from the Secondary Uses Service (SUS) database in England and vaccination histories from the National Immunisation Management System (NIMS); prior infections were obtained from the UK Health Security Agency's Second-Generation Surveillance Systems. The relative incidence (RI) of admission within 0 to 6 and 7 to 14 days of vaccination compared with periods outside these risk windows stratified by age, dose, and prior SARS-CoV-2 infection for individuals aged 12 to 101 years was estimated. The RI within 27 days of an infection was assessed in the same model. There were 2,284 admissions for myocarditis and 1,651 for pericarditis in the study period. Elevated RIs were only observed in 16- to 39-year-olds 0 to 6 days postvaccination, mainly in males for myocarditis. Both mRNA vaccines showed elevated RIs after first, second, and third doses with the highest RIs after a second dose 5.34 (95% confidence interval (CI) [3.81, 7.48]; p < 0.001) for BNT162b2 and 56.48 (95% CI [33.95, 93.97]; p < 0.001) for mRNA-1273 compared with 4.38 (95% CI [2.59, 7.38]; p < 0.001) and 7.88 (95% CI [4.02, 15.44]; p < 0.001), respectively, after a third dose. For ChAdOx1-S, an elevated RI was only observed after a first dose, RI 5.23 (95% CI [2.48, 11.01]; p < 0.001). An elevated risk of admission for pericarditis was only observed 0 to 6 days after a second dose of mRNA-1273 vaccine in 16 to 39 year olds, RI 4.84 (95% CI [1.62, 14.01]; p = 0.004). RIs were lower in those with a prior SARS-CoV-2 infection than in those without, 2.47 (95% CI [1.32,4.63]; p = 0.005) versus 4.45 (95% [3.12, 6.34]; p = 0.001) after a second BNT162b2 dose, and 19.07 (95% CI [8.62, 42.19]; p < 0.001) versus 37.2 (95% CI [22.18, 62.38]; p < 0.001) for mRNA-1273 (myocarditis and pericarditis outcomes combined). RIs 1 to 27 days postinfection were elevated in all ages and were marginally lower for breakthrough infections, 2.33 (95% CI [1.96, 2.76]; p < 0.001) compared with 3.32 (95% CI [2.54, 4.33]; p < 0.001) in vaccine-naïve individuals respectively.We observed an increased risk of myocarditis within the first week after priming and booster doses of mRNA vaccines, predominantly in males under 40 years with the highest risks after a second dose. The risk difference between the second and the third doses was particularly marked for the mRNA-1273 vaccine that contains half the amount of mRNA when used for boosting than priming. The lower risk in those with prior SARS-CoV-2 infection, and lack of an enhanced effect post-booster, does not suggest a spike-directed immune mechanism. Research to understand the mechanism of vaccine-associated myocarditis and to document the risk with bivalent mRNA vaccines is warranted." @default.
• W4379744348 created "2023-06-08" @default.
• W4379744348 creator A5001827751 @default.
• W4379744348 creator A5054039682 @default.
• W4379744348 creator A5072485453 @default.
• W4379744348 creator A5073763711 @default.
• W4379744348 date "2023-06-07" @default.
• W4379744348 modified "2023-09-23" @default.
• W4379744348 title "Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England" @default.
• W4379744348 cites W2058837954 @default.
• W4379744348 cites W2195401421 @default.
• W4379744348 cites W3093367571 @default.
• W4379744348 cites W3128853581 @default.
• W4379744348 cites W3145166616 @default.
• W4379744348 cites W3177443097 @default.
• W4379744348 cites W3195586393 @default.
• W4379744348 cites W3197105385 @default.
• W4379744348 cites W4200153303 @default.
• W4379744348 cites W4200368736 @default.
• W4379744348 cites W4200420340 @default.
• W4379744348 cites W4200563579 @default.
• W4379744348 cites W4205142464 @default.
• W4379744348 cites W4206069935 @default.
• W4379744348 cites W4214903451 @default.
• W4379744348 cites W4220653817 @default.
• W4379744348 cites W4220909091 @default.
• W4379744348 cites W4220918556 @default.
• W4379744348 cites W4224244510 @default.
• W4379744348 cites W4225711802 @default.
• W4379744348 cites W4226248453 @default.
• W4379744348 cites W4281643894 @default.
• W4379744348 cites W4281717376 @default.
• W4379744348 cites W4284964299 @default.
• W4379744348 cites W4288441808 @default.
• W4379744348 cites W4292582838 @default.
• W4379744348 cites W4298145582 @default.
• W4379744348 cites W4309667501 @default.
• W4379744348 cites W4318815788 @default.
• W4379744348 doi "https://doi.org/10.1371/journal.pmed.1004245" @default.
• W4379744348 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37285378" @default.
• W4379744348 hasPublicationYear "2023" @default.
• W4379744348 type Work @default.
• W4379744348 citedByCount "1" @default.
• W4379744348 countsByYear W43797443482023 @default.
• W4379744348 crossrefType "journal-article" @default.
• W4379744348 hasAuthorship W4379744348A5001827751 @default.
• W4379744348 hasAuthorship W4379744348A5054039682 @default.
• W4379744348 hasAuthorship W4379744348A5072485453 @default.
• W4379744348 hasAuthorship W4379744348A5073763711 @default.
• W4379744348 hasBestOaLocation W43797443481 @default.
• W4379744348 hasConcept C12590561 @default.
• W4379744348 hasConcept C126322002 @default.
• W4379744348 hasConcept C203014093 @default.
• W4379744348 hasConcept C22070199 @default.
• W4379744348 hasConcept C2522874641 @default.
• W4379744348 hasConcept C2780875844 @default.
• W4379744348 hasConcept C2781001862 @default.
• W4379744348 hasConcept C32611913 @default.
• W4379744348 hasConcept C71924100 @default.
• W4379744348 hasConceptScore W4379744348C12590561 @default.
• W4379744348 hasConceptScore W4379744348C126322002 @default.
• W4379744348 hasConceptScore W4379744348C203014093 @default.
• W4379744348 hasConceptScore W4379744348C22070199 @default.
• W4379744348 hasConceptScore W4379744348C2522874641 @default.
• W4379744348 hasConceptScore W4379744348C2780875844 @default.
• W4379744348 hasConceptScore W4379744348C2781001862 @default.
• W4379744348 hasConceptScore W4379744348C32611913 @default.
• W4379744348 hasConceptScore W4379744348C71924100 @default.
• W4379744348 hasFunder F4320318095 @default.
• W4379744348 hasIssue "6" @default.
• W4379744348 hasLocation W43797443481 @default.
• W4379744348 hasLocation W43797443482 @default.
• W4379744348 hasOpenAccess W4379744348 @default.
• W4379744348 hasPrimaryLocation W43797443481 @default.
• W4379744348 hasRelatedWork W4283514019 @default.
• W4379744348 hasRelatedWork W4286686549 @default.
• W4379744348 hasRelatedWork W4296528659 @default.
• W4379744348 hasRelatedWork W4301754360 @default.
• W4379744348 hasRelatedWork W4306157968 @default.
• W4379744348 hasRelatedWork W4306385348 @default.
• W4379744348 hasRelatedWork W4307191900 @default.
• W4379744348 hasRelatedWork W4309075216 @default.
• W4379744348 hasRelatedWork W4319460085 @default.
• W4379744348 hasRelatedWork W4361212986 @default.
• W4379744348 hasVolume "20" @default.
• W4379744348 isParatext "false" @default.
• W4379744348 isRetracted "false" @default.
• W4379744348 workType "article" @default.